Similarly, a Canadian series of 12 HAE patients, refractory to LTP with C1-INH concentrate, showed that lanadelumab could attain better disease control and minimize the burden of treatment, with a 72% reduction in attack rate [15]. Here, SERPING1 is linked to hereditary angioedema.